Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pediatric ambulatory pertussis epidemiology in France, recent updates.

Infectious diseases now·2023
Same author

Evaluation of an 'all-in-one' seven-day whole-genome sequencing solution in the investigation of a Staphylococcus aureus outbreak in a neonatal intensive care unit.

The Journal of hospital infection·2019
Same author

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2018
Same author

Antimicrobial treatment of ENT infections.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2018
Same author

Guidelines for the management of acne: recommendations from a French multidisciplinary group.

The British journal of dermatology·2017
Same author

[Not Available].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2016
Same journal

Family experiences of paediatric palliative care during hospital-at-home: a systematic review.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2026
Same journal

Knowledge of maternity caregivers on vaccination BCG recommendations and circuits.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2026
Same journal

"CRANIOQUALITY study: Quality of life in children with non-syndromic craniosynostosis after surgery".

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2026
Same journal

Chronological evolution of brain imaging of hemiconvulsion-hemiplegia-epilepsy from 5 cases in Mayotte island.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2026
Same journal

Point-of-care capillary blood ketone testing to predict the need for intravenous or nasogastric tube rehydration in children with acute gastroenteritis.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2026
Same journal

Transition practices of patients with inflammatory bowel disease from pediatric to adult healthcare systems. Results from a national survey.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2026
See all related articles

Related Experiment Video

Updated: May 12, 2026

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

[Pharmaceutical updates]

O Romain1

  • 1Service de pédiatrie et réanimation néonatale, hôpital Antoine-Béclère, hôpitaux universitaires Paris-Sud, 157, avenue Porte-de-Trivaux, 92140 Clamart, France.

Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie
|April 17, 2013
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Related Experiment Videos

Last Updated: May 12, 2026

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021